• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

ECTRIMS 2022 SLIDE DECK

November 10, 2022  

ECTRIMS 2022 HIGHLIGHTS – SATURDAY, OCTOBER 29 EDITION

October 29, 2022  

ECTRIMS 2022 HIGHLIGHTS – FRIDAY, OCTOBER 28 EDITION

October 28, 2022  

ECTRIMS 2022 HIGHLIGHTS – THURSDAY, OCTOBER 27 EDITION

October 27, 2022  

Re-evaluating the benefit-risk of high-efficacy treatment in MS

October 3, 2022  

Three biomarkers of DMT adverse effects proposed

August 25, 2022  

CLINICAL CASES IN MS – CASE 6: DIAGNOSTIC DILEMMA

August 22, 2022  

Is a cell-depleting DMT safe prior to HSCT?

August 9, 2022  

COVID-19 and MS – updated findings

July 28, 2022  

Key changes in Canadian MS care during the pandemic

July 7, 2022  
Previous
11
12
13
14
15
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions